A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine Abstract #2286

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.
Aim(s): The effects of adding the radiosensitiser capecitabine were explored in patients with metastatic or otherwise inoperable GEPNETs receiving treatment with 177Lu-DOTATATE.
Materials and methods: The study was a two-arm randomized controlled, prospective, non-blinded study protocol opening in 2006. Subjects were assigned to treatment arms of LuTate alone (‘control’) or in combination with capecitabine (‘investigational’). LuTate in both arms was administered as four equal administrations with an intended cumulative dose of 800 mCi (29.6 GBq). Capecitabine treatment comprised 1650 mg/m2/day in two divided doses for first two weeks of each cycle starting on the morning of the day of administration of LuTate. OS, PFS and haematological toxicity were assessed. Wider availability of LuTate therapy on compassionate grounds lead to increasing patient request for LuTate therapy alone. Trial recruitment was terminated in 2013.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Wouter van der Zwan

To read results and conclusion, please login ...

Further abstracts you may be interested in

#888 Capecitabine (Cp) and Somatostatine Analog (SSA) Suitable Treatment for Progressing G1-G2 Neuroendocrine Tumors (WD NET)
Introduction: Results from phase II and non-randomized trials with metronomic 5-FU in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
Keywords: capecitabine
#932 Hematological Toxicity of Combined Lutetium-177 Octreotate Radiopeptide-Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors Followed Long-Term
Introduction: Combination radiopeptide therapy (PRRT) with radiosensitizing chemotherapy of gastroenteropancreatic neuroendocrine tumors (GEP NETs) may improve efficacy, but has the potential to increase myelotoxicity.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Murali Kesavan
Keywords: PRRT, GEP-NET
#1125 Efficacy of PRRT in Metastatic Neuroendocrine Tumors; A Retrospective Large Single Institutional Study
Introduction: PRRT is a well-documented and well-established treatment for metastatic neuroendocrine tumours. However retrospective studies detailing the efficacy of PRRT are lacking.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Haamid Jan
Authors: Jan H, Wyld D, Burge M, ...
#1128 FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) After Peptide Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-PRRT).
Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
#1132 177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs
Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini